# Semaglutide Slowed a Blood-Based Dementia Risk Score in Older Heart Patients

*Semaglutide attenuates a proteomics-based dementia risk signature in older adults with overweight or obesity and cardiovascular disease without diabetes: A post hoc analysis of the SELECT phase 3 trial.*

- **Evidence Level**: Moderate
- **Publication Types**: Journal Article
- **Journal**: Alzheimer's & dementia (Amsterdam, Netherlands)
- **Sample Size**: 2,970 adults aged 65+ with overweight/obesity and heart disease, no diabetes
- **Authors**: Jiménez-Mausbach M, Tijms BM, Paterson C, Refsgaard JC
- **Published**: 2026-08-08
- **Topics**: GLP-1, semaglutide, brain health
- **DOI**: https://doi.org/10.1002/dad2.70432
- **Original Source**: https://pubmed.ncbi.nlm.nih.gov/42571323/

## Summary

Older adults with excess weight and heart disease but no diabetes took semaglutide or a placebo for two years. A 25-protein blood test that predicts future dementia risk rose much less in the semaglutide group. This isn't proof of fewer dementia cases, just a slower rise in a risk marker. Still, it adds to the idea that GLP-1 drugs may do something for the aging brain.

## Practical Takeaway

This analysis suggests GLP-1 drugs may affect brain-related blood markers, though actual dementia outcomes remain untested.

---

_Canonical: https://longevity-switzerland.com/en/research/semaglutide-slowed-a-blood-based-dementia-risk-score-in-older-heart-patients · Part of Longevity Cities · Updated 2026-08-08_